65,437 trials
Obesity
Primary: Percentage Change From Baseline in Body Weight at Week 12 — -1.86; -2.84; -3.41; -3.80 Percent Change
Coronary Angioplasty
Primary: Dose Use of Midazolam Medication (mg) — 3.0; 1.2 mg — p=<0.01
Bladder Cancer
Primary: Pathologic Response Rate — 57 percentage of participants
C. Difficile · Diarrhea · Enterocolitis
Primary: Change in Total Median Total Colony Forming Units (CFU) of C. Difficile Identified in the Hospital Room Environment for Each Antibiotic Treatment Group. — 56; 33; 149; 7…
Premature Infants
Primary: Duration of Home Oxygen Therapy — 66; 58 Days — p=<0.03
Complicated Urinary Tract Infections
Primary: Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit — 363; 382; 51; 7 Participants
Atrial Fibrillation
Primary: Stroke (Hemorrhagic, Ischemic, or Stroke of Uncertain Classification) — 0.90; 1.01; 0.64; 0.99 Incidence rate per 100 person-years
Insomnia · Cancer
Primary: Insomnia Severity Index (ISI) at Baseline — 17.6; 18.5 score on a scale
Benign Prostatic Hyperplasia · Overactive Bladder
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per Day — -2.00; -1.62 micturitions per day — p=0.039
Asthma
Primary: Number of Participants With Any Adverse Event (AE) or Adverse Drug Reaction (ADR) — 110; 0 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Number of Participants With and Without Hypersensitivity Reaction — 9; 6; 49; 50 Participants
Lymphoma
Primary: Program Feasibility: Number of Participants Who Completed at Least 75% of the Treatment Sessions — 20 Participants
Sleep · Insomnia
Primary: Hemodynamic Stability (Phase I) — 0; 0; 0; 0 Participants
Healthy
Primary: Normalized LL-37 Expression — 100 percentage of baseline
Overcoming Resistance to Eating Cruciferous Vegetables
Primary: Differences Between Plain and Spiced Vegetables Intake — 134.1; 212.5; 204.8; 178.1 gram — p=0.001